Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Azn crawled time : 14:00 save search
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: -0.64%
H: 0.45%
C: -0.04%
million series trials program
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
Published: 2024-02-29 (Crawled : 14:00) - prnewswire.com
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: -3.11%
H: 0.0%
C: -0.24%
IONS | $42.2 2.75% 190K
|
Health Technology
|
| O: 0.82%
H: 0.33%
C: -3.64%
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: -0.28%
H: 0.06%
C: -1.55%
global commercial growth
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
Published: 2024-01-02 (Crawled : 14:00) - prnewswire.com
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: -0.76%
H: 2.65%
C: 2.33%
license astrazeneca global program therapeutics agreement
Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member
Published: 2023-11-20 (Crawled : 14:00) - globenewswire.com
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: -1.49%
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: -1.39%
H: 1.02%
C: 0.87%
therapeutics
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers
Published: 2023-11-09 (Crawled : 14:00) - globenewswire.com
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: 2.33%
H: 0.83%
C: -0.88%
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: 2.72%
H: 0.49%
C: -1.79%
ARTL | News | $1.3004 15K
|
Health Technology
|
| O: 3.47%
H: 0.0%
C: -11.41%
art27 art27.13 publication research
American Red Cross Elects Aradhana Sarin as New Member to National Board of Governors
Published: 2023-07-13 (Crawled : 14:00) - prnewswire.com
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: -0.3%
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: 1.47%
H: 0.52%
C: 0.39%
Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate
Published: 2023-07-11 (Crawled : 14:00) - biospace.com/
GNPX | $2.28 5.41% 12K
|
Health Technology
|
| O: 1.25%
H: 3.41%
C: -1.43%
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: -0.28%
H: 0.25%
C: -0.23%
fda lung drug candidate cancer cell designation therapy fast track designation
Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer
Published: 2023-06-28 (Crawled : 14:00) - biospace.com/
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -2.36%
GNPX | $2.28 5.41% 12K
|
Health Technology
|
| O: 14.85%
H: 1.18%
C: -7.27%
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: -0.29%
H: 0.13%
C: -0.7%
reqorsa fda lung cancer cell treatment designation therapy fast track designation
Injection Pen Market Size is Projected To Reach USD 80,511.51 Million By 2031, Growing at a CAGR of 7.8% | Valuates Reports
Published: 2023-05-23 (Crawled : 14:00) - prnewswire.com
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: 0.7%
H: 1.22%
C: -0.67%
NONOF | $126.262 2.1K
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: -3.5%
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: -0.25%
H: 0.69%
C: -2.24%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: -1.46%
reach growing injection market
Fortress Biotech to Participate in Two March 2023 Investor Conferences
Published: 2023-03-07 (Crawled : 14:00) - globenewswire.com
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: -2.57%
H: 1.62%
C: 1.62%
FBIO | $1.78 1.71% 74K
|
Health Technology
|
| O: 0.0%
H: 3.69%
C: 2.72%
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: 0.9%
H: 0.28%
C: -1.3%
biotech
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial
Published: 2023-03-06 (Crawled : 14:00) - biospace.com/
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: -1.01%
H: 0.59%
C: 0.03%
enhertu tumor trial
Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
Published: 2023-02-16 (Crawled : 14:00) - globenewswire.com
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: -2.87%
H: 0.88%
C: 0.88%
FBIO | $1.78 1.71% 74K
|
Health Technology
|
| O: 0.81%
H: 5.54%
C: 3.66%
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: -2.65%
H: 1.22%
C: 0.16%
cibmtr trial positive therapy
TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer
Published: 2023-01-30 (Crawled : 14:00) - biospace.com/
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: 1.3%
H: 0.06%
C: -0.81%
lung trial cancer initiated
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03
Published: 2022-12-07 (Crawled : 14:00) - biospace.com/
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: 0.45%
H: 0.64%
C: -0.03%
enhertu risk breast cancer her2- her2 metastatic breast cancer
Global Pharmacogenomics Market Analysis Report 2022: A $10.5+ Billion Market by 2026 - Long-term Forecast to 2031
Published: 2022-11-23 (Crawled : 14:00) - prnewswire.com
GLAXF | News | $20.305 630
|
Health Technology
|
| O: 1.83%
H: 0.0%
C: 0.0%
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: 1.44%
H: 1.0%
C: -1.09%
TMO | News | $574.855 4.83% 1.1M
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
GSK | News | $41.13 1.33% 1.1M
|
Health Technology
|
| O: -0.53%
H: 0.59%
C: 0.06%
ABT | News | $108.01 0.88% 1.2M
|
Health Technology
|
| O: 0.1%
H: 1.43%
C: 1.0%
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: 0.41%
H: 0.24%
C: -0.23%
global report market
Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Published: 2022-11-08 (Crawled : 14:00) - biospace.com/
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: 2.49%
H: 0.0%
C: -1.6%
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: 0.2%
H: 0.96%
C: 0.18%
ARTL | News | $1.3004 15K
|
Health Technology
|
| O: 0.0%
H: 4.74%
C: 4.74%
financial update results
Red Biotechnology Market to Exceed US$ 609.6 Bn by 2031: TMR Study
Published: 2022-08-19 (Crawled : 14:00) - prnewswire.com
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: 3.04%
H: 0.12%
C: -2.22%
TAK | News | $13.4 0.3% 790K
|
Health Technology
|
| O: -2.05%
H: 0.29%
C: 0.07%
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: 0.54%
H: 1.24%
C: 0.63%
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: 0.01%
H: 2.09%
C: 1.58%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: -0.62%
H: 0.57%
C: -0.42%
GILD | $67.25 0.45% 2M
|
Health Technology
|
| O: -0.25%
H: 1.19%
C: 0.49%
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: 0.78%
H: 0.49%
C: 0.22%
study market
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex
Published: 2022-08-11 (Crawled : 14:00) - biospace.com/
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: -0.07%
H: 0.12%
C: -2.89%
FBIO | $1.78 1.71% 74K
|
Health Technology
|
| O: 0.83%
H: 7.38%
C: 5.74%
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: -1.89%
H: 0.0%
C: -0.61%
biotech grant study phase 2
Global Cough Syrup Market Report (2022 to 2028) - Featuring AstraZeneca, Abbott Laboratories, Acella Pharmaceuticals and Glenmark Pharmaceuticals Among Others
Published: 2022-07-01 (Crawled : 14:00) - prnewswire.com
RBGPF | News | $52.06 4.8K
|
Consumer Non-Durables
|
| O: 0.2%
H: 4.46%
C: 0.03%
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: -3.88%
H: 6.2%
C: 5.52%
RBGLY | News | $10.59 850K
|
Manufacturing
|
| O: -1.05%
H: 1.59%
C: 1.53%
ABT | News | $108.01 0.88% 1.2M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: -2.92%
H: 0.0%
C: 0.0%
report market
Biologic Therapy Market Information: By Product and Geography - Global Forecast till 2025
Published: 2022-06-17 (Crawled : 14:00) - prnewswire.com
GLAXF | News | $20.305 630
|
Health Technology
|
| O: 0.01%
H: 0.17%
C: 0.17%
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -1.76%
H: 5.75%
C: 5.5%
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: -0.64%
NVSEF | News | $95.11 490
|
Health Technology
|
| O: 0.74%
H: 0.52%
C: -3.23%
NVS | News | $97.31 2.3% 2.3M
|
Health Technology
|
| O: 0.07%
H: 0.0%
C: 0.0%
JNJ | News | $150.09 0.65% 3.9M
|
Health Technology
|
| O: 1.35%
H: 0.0%
C: 0.0%
GSK | News | $41.13 1.33% 1.1M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
ABBV | News | $170.19 1.37% 1.6M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: 0.0%
AZN | News | $70.87 1.06% 3M
|
Health Technology
|
| O: 0.59%
H: 0.0%
C: 0.0%
therapy market
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.7 78.19% 1.7M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
PALI | $6.29 27.59% 22M
|
Manufacturing
MCRB | $0.7902 26.51% 6.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.